Skip navigation

Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis

Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis

Harbige, Laurence S. and Sharief, Mohammad K. (2007) Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. British Journal of Nutrition, 98 (S1). S46-S53. ISSN 0007-1145 (doi:10.1017/S0007114507833010)

[img]
Preview
PDF ((c) The Authors 2007)
HarbigeL2007_0064.pdf - Published Version

Download (329kB)

Abstract

Epidemiological, biochemical, animal model and clinical trial data described in this overview strongly suggest that polyunsaturated fatty acids, particularly n-6 fatty acids, have a role in the pathogenesis and treatment of multiple sclerosis (MS). Data presented provides further evidence for a disturbance in n-6 fatty acid metabolism in MS. Disturbance of n-6 fatty acid metabolism and dysregulation of cytokines are shown to be linked and a "proof of concept clinical trial" further supports such a hypothesis. In a randomised double-blind, placebo controlled trial of a high dose and low dose selected GLA (18:3n-6)-rich oil and placebo control, the high dose had a marked clinical effect in relapsing-remitting MS, significantly decreasing the relapse rate and the progression of disease. Laboratory findings paralleled clinical changes in the placebo group in that production of mononuclear cell pro-inflammatory cytokines (TNF-alpha, IL-1 beta) was increased and anti-inflammatory TGF-beta markedly decreased with loss of membrane n-6 fatty acids linoleic (18:2n-6) and arachidonic acids (20:4n-6). In contrast there were no such changes in the high dose group. The improvement in disability (Expanded Disability Status Scale) in the high dose suggests there maybe a beneficial effect on neuronal lipids and neural function in MS. Thus disturbed n-6 fatty acid metabolism in MS gives rise to loss of membrane long chain n-6 fatty acids and loss of the anti-inflammatory regulatory cytokine TGF-beta, particularly during the relapse phase, as well as loss of these important neural fatty acids for CNS structure and function and consequent long term neurological deficit in MS.

Item Type: Article
Additional Information: Presented at 1st International Immunonutrition Workshop Valencia, Spain, 3-5 Oct 2007.
Uncontrolled Keywords: multiple sclerosis, linoleic acid, gamma-linolenic acid, arachidonic acid, clinical trials, cytokines
Subjects: R Medicine > RM Therapeutics. Pharmacology
Faculty / Department / Research Group: Faculty of Engineering & Science > Department of Life & Sports Sciences
Related URLs:
Last Modified: 05 Dec 2016 16:21
Selected for GREAT 2016: None
Selected for GREAT 2017: None
Selected for GREAT 2018: None
URI: http://gala.gre.ac.uk/id/eprint/2507

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics